Contribution of the CHEK2 1100delC variant to risk of multiple colorectal adenoma and carcinoma

被引:26
|
作者
Lipton, L
Fleischmann, C
Sieber, OA
Thomas, HJW
Hodgson, SV
Tomlinson, IPM
Houlston, RS
机构
[1] Inst Canc Res, Sect Canc Genet, Sutton SM2 5NG, Surrey, England
[2] London Res Inst, Mol & Populat Genet Lab, Canc Res UK, London WC2A 3PX, England
[3] St Marks Hosp, Canc Res UK Colorectal Unit, Harrow HA1 3UJ, Middx, England
[4] Guys Hosp, Dept Clin Genet, London SE1 9RT, England
关键词
CHEK2; 1100deIC; colorectal; neoplasm;
D O I
10.1016/S0304-3835(03)00391-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aneuploidy is a characteristic of a subset of colorectal tumours. CHEK2 (also known as CHK2) is one of the cell cycle checkpoint genes coding for a family of proteins that sense damage in eukaryotic cells. Germline variation in CHEK2 has recently been shown to confer cancer susceptibility. Heterozygous mutations have been identified in patients with TP53-negative Li-Fraumeni syndrome. Furthermore, the CHEK2 1100delC variant carried by 1% of the population has been shown to act as a low penetrance allele for both breast and prostate cancers. To further our knowledge about the contribution of CHEK2 1100delC to cancer incidence we have analysed a series of 149 patients with multiple colorectal adenomas some of whom developed colorectal cancer. The CHEK2 1100delC allele was not over-represented in cases suggesting that this variant is not associated with an increased risk of colorectal disease. (C) 2003 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:149 / 152
页数:4
相关论文
共 50 条
  • [21] CHEK2*1100delC homozygosity in the Netherlands—prevalence and risk of breast and lung cancer
    Petra EA Huijts
    Antoinette Hollestelle
    Brunilda Balliu
    Jeanine J Houwing-Duistermaat
    Caro M Meijers
    Jannet C Blom
    Bahar Ozturk
    Elly MM Krol-Warmerdam
    Juul Wijnen
    Els MJJ Berns
    John WM Martens
    Caroline Seynaeve
    Lambertus A Kiemeney
    Henricus F van der Heijden
    Rob AEM Tollenaar
    Peter Devilee
    Christi J van Asperen
    European Journal of Human Genetics, 2014, 22 : 46 - 51
  • [22] The CHEK2 1100delC mutation identifies families with a hereditary breast and colorectal cancer phenotype
    Meijers-Heijboer, H
    Wijnen, J
    Vasen, H
    Wasielewski, M
    Wagner, A
    Hollestelle, A
    Elstrodt, F
    van den Bos, R
    de Snoo, A
    Fat, GTA
    Brekelmans, C
    Jagmohan, S
    Franken, P
    Verkuijlen, P
    van den Ouweland, A
    Chapman, P
    Tops, C
    Möslein, G
    Burn, J
    Lynch, H
    Klijn, J
    Fodde, R
    Schutte, M
    AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (05) : 1308 - 1314
  • [23] CHEK2*1100delC homozygosity is associated with a high breast cancer risk in women
    Adank, Muriel A.
    Jonker, Marianne A.
    Kluijt, Irma
    van Mil, Saskia E.
    Oldenburg, Rogier A.
    Mooi, Wolter J.
    Hogervorst, Frans B. L.
    van den Ouweland, Ans M. W.
    Gille, Johan J. P.
    Schmidt, Marjanka K.
    van der Vaart, Aad W.
    Meijers-Heijboer, Hanne
    Waisfisz, Quinten
    JOURNAL OF MEDICAL GENETICS, 2011, 48 (12) : 860 - 863
  • [24] CHEK2:1100delC and female breast cancer in the United States
    Pereira, LHM
    Sigurdson, AJ
    Doody, MM
    Pineda, MA
    Alexander, BH
    Greene, MH
    Struewing, JP
    INTERNATIONAL JOURNAL OF CANCER, 2004, 112 (03) : 541 - 543
  • [25] CHEK2 1100delC mutation in Russian ovarian cancer patients
    Nadezhda Yu Krylova
    Daria N Ponomariova
    Natalia Yu Sherina
    Natalia Yu Ogorodnikova
    Denis A Logvinov
    Natalia V Porhanova
    Oksana S Lobeiko
    Adel F Urmancheyeva
    Sergey Ya Maximov
    Alexandr V Togo
    Evgeny N Suspitsin
    Evgeny N Imyanitov
    Hereditary Cancer in Clinical Practice, 5
  • [26] The CHEK2 1100delC allele is not relevant for risk assessment in HNPCC and HBCC Spanish families
    Ana Sánchez de Abajo
    Miguel de la Hoya
    Javier Godino
    Vicente Furió
    Alicia Tosar
    Pedro Pérez-Segura
    Eduardo Díaz-Rubio
    Trinidad Caldés
    Familial Cancer, 2005, 4 : 183 - 186
  • [27] CHEK2*1100delC heterozygosity predicts increased risk of breast cancer and poor outcome
    Nature Clinical Practice Oncology, 2007, 4 (4): : 212 - 213
  • [28] CHEK2☆1100delC homozygosity in the Netherlands-prevalence and risk of breast and lung cancer
    Huijts, Petra E. A.
    Hollestelle, Antoinette
    Balliu, Brunilda
    Houwing-Duistermaat, Jeanine J.
    Meijers, Caro M.
    Blom, Jannet C.
    Ozturk, Bahar
    Krol-Warmerdam, Elly M. M.
    Wijnen, Juul
    Berns, Els M. J. J.
    Martens, John W. M.
    Seynaeve, Caroline
    Kiemeney, Lambertus A.
    van der Heijden, Henricus F.
    Tollenaar, Rob A. E. M.
    Devilee, Peter
    van Asperen, Christi J.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2014, 22 (01) : 46 - 51
  • [29] A multicenter study of cancer incidence in CHEK2 1100delC mutation carriers
    Thompson, Deborah
    Seal, Sheila
    Schutte, Mieke
    McGuffog, Lesley
    Barfoot, Rita
    Renwick, Anthony
    Eeles, Rosalind
    Sodha, Nayanta
    Houlston, Richard
    Shanley, Susan
    Klijn, Jan
    Wasielewski, Marijke
    Chang-Claude, Jenny
    Futreal, P. Andrew
    Weber, Barbara L.
    Nathanson, Katherine L.
    Stratton, Michael
    Meijers-Heijboer, Hanne
    Rahman, Nazneen
    Easton, Douglas F.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2006, 15 (12) : 2542 - 2545
  • [30] Excess Risk for Contralateral Breast Cancer in CHEK2*1100delC Germline Mutation Carriers
    Annegien Broeks
    Lot de Witte
    Anke Nooijen
    Angelina Huseinovic
    Jan G.M. Klijn
    Flora E. van Leeuwen
    Nicola S. Russell
    Laura J. van't Veer
    Breast Cancer Research and Treatment, 2004, 83 : 91 - 93